Spinal Neoplasms
14
2
4
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
7.1%
1 terminated out of 14 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (14)
Intradurale Spinal Tumors: Management and Treatment
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
Evaluation of Single Session Stereotactic Body Radiotherapy
Standard Dose Versus High Dose Stereotactic Spine Radiosurgery for Metastatic Spinal Neoplasms
Separation Surgery Followed by Stereotactic Ablative Body Radiotherapy (SABR) Versus SABR Alone for Spinal Metastases
Overcome, a Program of Therapeutic Exercise and Functional Recovery to Improve the Functional Capacity of Women With Breast Cancer and Bone Metastases
PASS OCT® Post-market Clinical Follow-up
Stereotactic Body Radiotherapy Followed by Surgical Stabilization in Spinal Metastases
UNiD 3D VBR Register
Evaluation of Effectiveness of CyberKnife Stereotactic Radiosurgery for Spinal Tumors
Clinical Trial of a Serious Game for Individuals With SCI/D
Surgical Treatment of Intra-spinal Canal Tumors Via Trans-Quadrant Channel
Intra-Operative Dural Brachytherapy With Yttrium-90 Plaque Applicators
Protection of Autonomic Nervous System During Lower Spine Surgical Procedures: A Safety and Feasibility Study